Nature Medicine, Published online: 03 April 2026; doi:10.1038/s41591-026-04305-wTo accelerate therapeutic development and equip stakeholders with clear benchmarks, the authors outline target product profiles for therapies designed to delay or prevent the onset of clinical symptoms of Alzheimer’s disease.

Nature Cancer, Published online: 03 April 2026; doi:10.1038/s43018-026-01142-1Izar and colleagues review the insights into cancer biology gained via single-cell analyses and spatial profiling and overview the challenges and opportunities associated with the implementation of these approaches to guide clinical discovery.

Nature Medicine, Published online: 02 April 2026; doi:10.1038/s41591-026-04379-6Author Correction: Real-world clinical utility of tumor whole-genome sequencing in solid cancers

Nature Medicine, Published online: 02 April 2026; doi:10.1038/s41591-026-04281-1A prespecified analysis from the SELECT trial showed that semaglutide reduces major adverse cardiovascular events by 20% compared with placebo, particularly in patients at high risk of fibrosis, as indicated by the Fibrosis-4 index.

Nature, Published online: 02 April 2026; doi:10.1038/d41586-026-00809-0Chemistry that forms an omnipresent type of carbon–carbon bond enables the modular synthesis of 3D organic molecules — a boon for drug discovery and materials design.

The E3-ome defines the human repertoire of ubiquitin E3 ligases, creating a unified resource that maps their diversity across the ubiquitin and ubiquitin-like systems. By consolidating fragmented knowledge, this framework provides a foundation for studying ubiquitin signaling and accelerating discovery.

Deep proteome profiling of over 5,000 cerebrospinal fluid samples by mass spectrometry maps protein alterations across major neurological disorders, resolving key sources of variation as well as shared and disease-specific signatures. This framework yields a 22-protein assay that improves the differential diagnosis of multiple sclerosis from other inflammatory conditions, particularly in diagnostically challenging oligoclonal band-negative individuals.